Mageau A, Tchen J, Ferré VM, Nicaise-Roland P, Descamps D, Delory N, François C, Mendes C, Papo T, Goulenok T, Charles N, Sacré K. J Autoimmun. 2022 Dec 19;134:102987. doi: 10.1016/j.jaut.2022.102987. Online ahead of print. PMID: 36563528
Objective: To evaluate the specific response of SLE patients to BNT162b2 vaccination and its impact on autoimmunity defined as in vivo production of interferon-alpha (IFNα) by plasmacytoid dendritic cells (pDCs) and autoreactive immune responses.
Methods: Our prospective study included SLE patients and healthy volunteers (HV) who received 2 doses of BNT162b2 vaccine 4 weeks apart. Subjects under immunosuppressive drugs or with evidence of prior COVID-19 were excluded. IgG anti-Spike SARS-CoV-2 (anti-S) antibodies, anti-S specific-B cells, anti-S specific T cells, in vivo INF-α production by pDCs, activation marker expression by pDCs and autoreactive anti-nuclear T cells were quantified before first injection, before second injection, and 3 and 6 months after first injection.
Results: Vaccinated SLE patients produced significantly lower IgG antibodies and specific B cells against SARS-CoV-2 as compared to HV. In contrast, anti-S T cell response did not significantly differ between SLE patients and HV. Following vaccination, the surface expression of HLA-DR and CD86 and the in vivo production of IFNα by pDCs significantly increased in SLE patients. The boosted expression of HLA-DR on pDCs induced by BNT162b2 vaccine correlated with the overall immune responses against SARS-CoV-2 (anti-S antibodies: r = 0.27 [0.05-0.46], p = 0.02; anti-S B cells: r = 0.19 [-0.03-0.39], p = 0.09); anti-S T cells: r = 0.28 [0.05-0.47], p = 0.016). Eventually, anti-SARS-CoV-2 vaccination was associated with an overall decrease of autoreactive T cells (slope = – 0.00067, p = 0.015).
Conclusion: BNT162b2 vaccine induces a transient in vivo activation of pDCs in SLE that contributes to the immune responses against SARS-CoV-2. Unexpectedly BNT162b2 vaccine also dampens the pool of circulating autoreactive T cells, suggesting that vaccination may have a beneficial impact on SLE disease.
Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. J Hepatol. 2022 Jul 20:S0168-8278(22)02942-7. doi: 10.1016/j.jhep.2022.07.008. Online ahead of print. PMID: 35868584
La pandémie de COVID-19 a présenté un sérieux défi à la communauté hépatologique, en particulier aux professionnels de la santé et aux patients. Alors que le développement rapide de vaccins et de traitements sûrs et efficaces a amélioré le paysage clinique, l’émergence de la variante omicron a présenté de nouveaux défis. Ainsi, il est opportun que l’Association européenne pour l’étude du foie fournisse un résumé des dernières données sur l’impact du COVID-19 sur le foie et publie des conseils sur la prise en charge des patients atteints d’une maladie hépatique chronique, d’un cancer hépatobiliaire et d’antécédents. transplantation hépatique, alors que le monde continue de faire face aux conséquences de la pandémie de COVID-19.
Baiges A, Cerda E, Amicone C, Téllez L, Alvarado-Tapias E, Puente A, Fortea JI, Llop E, Rocha F, Orts L, Ros-Fargas O, Vizcarra P, Zekrini K, Lounes OA, Touati G, Jiménez-Esquivel N, Serrano MJ, Falgà A, Magaz M, Olivas P, Betancourt F, Perez-Campuzano V, Turon F, Payancé A, Goria O, Rautou PE, Hernández-Gea V, Villanueva C, Albillos A, Plessier A, García-Pagán JC. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1525-1533.e5. doi: 10.1016/j.cgh.2021.12.032. Epub 2021 Dec 27. PMID: 34968728
Les maladies vasculaires hépatiques (VLD) sont représentées principalement par la maladie vasculaire portosinusoïdale (PSVD), la thrombose veineuse splanchnique non cirrhotique (SVT) et le syndrome de Budd Chiari (BCS). On ne sait pas si les patients atteints de VLD constituent une population à haut risque de complications et d’une plus grande mortalité liée à la maladie à coronavirus 2019 (COVID-19) due à une infection par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2). Notre objectif était d’évaluer la prévalence et la gravité de l’infection par le SRAS-CoV-2 chez les patients atteints de VLD, ainsi que d’évaluer son impact sur la décompensation hépatique et la survie.
Systemic lupus erythematosus flare following SARS-CoV2 infection: the implication of IFNα and anti-IFNα autoantibodies.
Mageau A, Nicaise Roland P, Goulenok T, Farkh C, Charles N, Sacre K. Clin Exp Rheumatol. 2022 Feb 16.
L’implication de l’interféron (IFN) de type 1 et des anticorps (Ac) anti-IFN de type 1 dans la physiopathologie du Lupus Erythémateux Systémique (LES) et de la réponse immune au cours de la COVID-19 pose la question du risque de poussées lupiques après une infection par le SARS-CoV-2. Nous rapportons ici le cas d’une patiente chez qui nous avons pu monitorer le taux d’IFNα, d’Ac anti-IFNα et d’Ac anti-ADN avant, pendant et après une infection par le COVID-19. L’évolution clinique mise en parallèle avec l’évolution de ces marqueurs immunologiques suggère un lien direct entre l’infection virale, la chute du taux d’Ac anti-IFNα et la poussée de LES qui s’en est suivie.
Renin-angiotensin system blockers and COVID-19.
Vidal-Petiot E, Gault N. BMC Med. 2021;19(1):136. 2021 Jun 4. doi:10.1186/s12916-021-02012-6
Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, de Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, Costagliola D, Vidal-Petiot E; French-Covid cohort investigators and study group. Fundam Clin Pharmacol. 2021 Apr 20. doi: 10.1111/fcp.12683. Online ahead of print. PMID: 33876439
SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study.
Mageau A, Aldebert G, Van Gysel D, Papo T, Timsit JF, Sacre K. Ann Rheum Dis. 2021 Mar 16:annrheumdis-2021-220010. doi: 10.1136/annrheumdis-2021-220010.
The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19.
Le Stang MB, Desenclos J, Flamant M, Chousterman BG, Tabibzadeh N. Front Physiol. 2021 Mar 11;12:613019. doi: 10.3389/fphys.2021.613019. eCollection 2021. PMID: 33776785
Arterial Thrombotic Events in Adult Inpatients With COVID-19.
Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K. Mayo Clin Proc. 2021 Feb;96(2):295-303. doi: 10.1016/j.mayocp.2020.11.018. Epub 2020 Nov 27. PMID: 33549252
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau C, Soulard P, Gouda Z, Cagninacci L, Monteiro AC, Hurtado-Nedelec M, Luce S, Bailly K, Andrieu M, Saintpierre B, Letourneur F, Jouan Y, Si-Tahar M, Baranek T, Paget C, Boitard C, Vallet-Pichard A, Gautier JF, Ajzenberg N, Terrier B, Pène F, Ghosn J, Lescure X, Yazdanpanah Y, Visseaux B, Descamps D, Timsit JF, Monteiro RC, Lehuen A. Nat Immunol. 2021 Feb 2. doi: 10.1038/s41590-021-00870-z. Online ahead of print. PMID: 33531712
Impact of the first Covid-19 outbreak on liver transplantation activity in France: A snapshot.
Turco C, Lim C, Soubrane O, Malaquin G, Kerbaul F, Bastien O, Conti F, Scatton O. Clin Res Hepatol Gastroenterol. 2020 Nov 8:101560. doi: 10.1016/j.clinre.2020.10.005. Online ahead of print. PMID: 33176991
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.
Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Burgio MD, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. JHEP Rep. 2021 Feb;3(1):100199. doi: 10.1016/j.jhepr.2020.100199. Epub 2020 Dec 22. PMID: 33163949
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E. J Hypertens. 2021 Feb 1;39(2):367-375. doi: 10.1097/HJH.0000000000002658. PMID: 33021511
Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: Results from the ApoCOVID study.
Tanaka S, De Tymowski C, Assadi M, Zappella N, Jean-Baptiste S, Robert T, Peoc’h K, Lortat-Jacob B, Fontaine L, Bouzid D, Tran-Dinh A, Tashk P, Meilhac O, Montravers P. PLoS One. 2020 Sep 24;15(9):e0239573. doi: 10.1371/journal.pone.0239573. eCollection 2020. PMID: 32970772
Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France.
Herpe G, Lederlin M, Naudin M, Ohana M, Chaumoitre K, Gregory J, Vilgrain V, Freitag CA, De Margerie-Mellon C, Flory V, Ludwig M, Mondot L, Fitton I, Jacquier ARR, Ardilouze P, Petit I, Gervaise A, Bayle O, Crombe A, Mekuko Sokeng M, Thomas C, Henry G, Bliah V, Le Tat T, Guillot MS, Gendrin P, Garetier M, Bertolle E, Montagne C, Langlet B, Kalaaji A, Kayayan H, Desmots F, Dhaene B, Saulnier PJ, Guillevin R, Bartoli JM, Beregi JP, Tasu JP. Radiology. 2021 Feb;298(2):E81-E87. doi: 10.1148/radiol.2020202568. Epub 2020 Sep 1. PMID: 32870139
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169. Epub 2020 Aug 4. PMID: 32835190
Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome.
Grégory J, Raynaud L, Galy A, Corre F, Bijot JC, Nguyen Y, Vilgrain V. Infect Dis (Lond). 2020 Nov;52(11):838-840. doi: 10.1080/23744235.2020.1792544. Epub 2020 Jul 13. PMID: 32657190
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
Biquard L, Valla D, Rautou PE. J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30. PMID: 32360995